Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on ...

Eli Lilly (LLY) reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street estimates and sending its stock up about 2% in pre-market trading. But the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Follow along for live updates on stocks, bonds and other markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Vance, a Catholic convert, accused the U.S. Conference of Catholic Bishops of resettling “illegal immigrants.” ...